| Name | Title | Contact Details |
|---|
Neurana Pharmaceuticals is a privately held clinical stage San Diego based specialty pharmaceutical company developing a novel treatment for acute muscle spasms. The Company was founded in 2013 by veteran biotech entrepreneurs David F. Hale and Jeffrey Raser to focus on central nervous system (CNS) diseases and disorders.
Highland Therapeutics Inc., a Toronto-based specialty pharmaceutical company. It is a specialty pharmaceutical company leveraging its proprietary technologies to optimize the delivery of previously approved drug products.
Medicis Pharmaceutical Corporation (Medicis) is an independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States of
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.